Logo

Kenneth Weg

Sep 10, 2015

Metamark Genetics has appointed Kenneth Weg as president and CEO. He succeeds Shawn Marcell, who resigned from his position to pursue other activities. Weg is a Metamark co-founder and current chairman of the board of directors. He has previously served as the president of the Worldwide Medicines Group at Bristol-Myers Squibb (BMS), where he was responsible for overseeing all ethical pharmaceuticals and over-the-counter medicines on a global basis. Weg also served as vice chairman of the BMS board of directors. Before his work at BMS, he held the position of non-executive chairman of Millennium Pharmaceuticals. He has also served on the boards of Fox Chase Cancer Center and AVEO Pharmaceuticals and is a current member of Karyopharm's board of directors.

Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.